AbCellera Biologics Inc. (ABCL) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 9 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for ABCL is $20.17, representing a +436.4% upside from the current price of $3.76. Price targets range from a low of $5.00 to a high of $34.00.
